Strides Pharma Science Limited (STAR.BO)
- Previous Close
789.65 - Open
795.40 - Bid 780.30 x --
- Ask 780.60 x --
- Day's Range
775.05 - 795.40 - 52 Week Range
530.70 - 1,675.25 - Volume
12,487 - Avg. Volume
30,815 - Market Cap (intraday)
72.099B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
20.92 - EPS (TTM)
37.30 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield 2.50 (0.32%)
- Ex-Dividend Date Sep 9, 2024
- 1y Target Est
1,013.50
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
www.strides.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: STAR.BO
View MorePerformance Overview: STAR.BO
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAR.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAR.BO
View MoreValuation Measures
Market Cap
72.10B
Enterprise Value
91.83B
Trailing P/E
20.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.63
Price/Book (mrq)
3.17
Enterprise Value/Revenue
2.08
Enterprise Value/EBITDA
10.58
Financial Highlights
Profitability and Income Statement
Profit Margin
78.71%
Return on Assets (ttm)
6.42%
Return on Equity (ttm)
17.58%
Revenue (ttm)
45.65B
Net Income Avi to Common (ttm)
4.05B
Diluted EPS (ttm)
37.30
Balance Sheet and Cash Flow
Total Cash (mrq)
2.06B
Total Debt/Equity (mrq)
72.67%
Levered Free Cash Flow (ttm)
1.93B